Israeli startup CytoReason today announced a partnership with Swiss multinational, Ferring Pharmaceuticals, to establish new treatments for inflammatory bowel disease (IBD).
This is the first collaboration between the two companies, pairing Ferring’s medical expertise with CytoReason’s artificial intelligence (AI) platform to build cell-centred disease models.
CytoReason is developing a...
_0.jpeg?itok=NpCbFI32 "The collaboration will use AI technology to accelerate the drug discovery process.")
